Navigating a healthcare "perfect storm," Commissioner Olivér Várhelyi outlined a clear vision at the 4th EU Health Summit on January 28, 2025, aimed at transforming European healthcare through innovation and strategic legislation.
Facing rising chronic diseases, high and increasing healthcare costs, shortages of healthcare professionals, and geopolitical challenges, Várhelyi positioned digital technologies and biotechnology at the core of future EU health policy. He emphasized the European Health Data Space as a foundational tool to enable secure data sharing among researchers, industry, and policymakers, aiming to accelerate scientific breakthroughs and unify the digital health market across member states.
A key concrete proposal from Várhelyi is the forthcoming Critical Medicines Act, designed to address structural dependencies exposed by the COVID-19 pandemic and frequent critical medicine shortages. This legislation intends to boost European pharmaceutical manufacturing and create market incentives, representing a significant shift toward increasing EU powers in supply chain resilience and pharmaceutical production capacity.
Complementing this, the proposed European Biotech Act aims to facilitate the commercialization of biotech innovations, combining artificial intelligence and health data to advance personalized medicine and develop novel therapies. Várhelyi also stressed the need to modernize pharmaceutical regulations and ensure safe, innovative, and available medical devices by conducting targeted regulatory assessments.
The Commissioner further aligned health policy with economic governance by highlighting the European Semester’s role in encouraging healthcare system reforms tailored to national challenges, signaling support for improved resilience amid workforce shortages and aging populations.
Stakeholders impacted include EU pharmaceutical producers who face increased regulatory and production expectations; EU consumers who could benefit from improved medicine availability and personalized care; national authorities targeted to implement healthcare reforms; and healthcare providers challenged by workforce shortages but supported through innovation incentives. While the proposals promote significant innovation advances and supply security, increased regulatory demands and potential shifts in market dynamics may require adaptation from industry and member states alike.
Várhelyi's speech signals incremental but decisive moves toward strengthening EU intervention and integration in healthcare innovation, security, and regulatory frameworks, with a balanced ambition to boost competitiveness while ensuring public trust and patient safety.